Q2 2026 Fresenius Medical Care AG Earnings Call Transcript
Key Points
- Fresenius Medical Care AG (FMS) delivered another quarter of highly profitable growth, with operating income growth accelerating to 23% and further margin expansion.
- The FME25+ transformation program delivered EUR67 million in sustainable savings during the quarter, supporting profitability improvements.
- The company completed its initial EUR1 billion share buyback program ahead of schedule and launched a second EUR1 billion program, underscoring disciplined capital allocation and shareholder returns.
- The 5008X rollout is accelerating as planned, with 227 clinics converted and over 600,000 treatments performed, including positive early patient outcomes such as 40% fewer muscle cramps.
- Value-Based Care segment showed strong improvement, with operating income increasing to EUR18 million from a EUR9 million loss in the prior year, driven by improved savings rates and contracting strength.
- Operating cash flow increased by 11% in the second quarter, driven by disciplined working capital management, while free cash flow remained stable at EUR625 million.
- US same-market treatment growth declined by 0.9% in the second quarter due to an operational miss in capturing fair market share of referrals, leading to a further softening in Q2 compared with Q1.
- The company now expects US same-market treatment growth for 2026 to be around the Q2 level, reflecting the compounding effect of lower first-half referrals on the rest of the year.
- Care Enablement earnings declined by 5% in the quarter, impacted by adverse regulatory pressure in China and increased inflationary pressures, including higher raw material costs and elevated logistics expenses related to the Middle East conflict.
- The European Commission's recommended revocation of the TAVNEOS marketing authorization led to a negative special item impact of EUR71 million from the impairment of intangible assets at Vifor Fresenius Medical Care Renal Pharma.
- TDAPA reimbursement benefits are expected to become a sizable headwind in the third and fourth quarters, resulting in negative earnings growth in the second half of 2026.
- The company faces ongoing headwinds from the ACA subsidy expiration, with an expected EUR50 million negative impact for the full year, as patients leave exchange plans due to affordability issues.
Ladies and gentlemen, welcome to the report on second quarter 2026 earnings release and conference call. I am Valentina Dekaros, call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Dr. Dominik Heger. Please go ahead.
Thank you, Valentina. I would like to welcome everyone to our earnings call for the second quarter of 2026. I appreciate your flexibility to join this earlier call. We felt it is more helpful to have the call earlier given that we had to publish earlier than originally planned. I do apologize for the inconvenience, in particular for those of you who are located in a different time zone or those of you who cover another company hosting a call in parallel right now.
As always, I start out the call by mentioning our cautionary language that is in our safe
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
